- ￥880
- Bioss
- bs-8641P
- 2025年10月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
500ug
| 产品编号 | bs-8641P |
| 英文名称 | ZDHHC-18 Antibody Blocking Peptide |
| 中文名称 | 锌指蛋白Zdhhc18封闭多肽 |
| 英文别名 | DHHC-18; DKFZp667O2416; Palmitoyltransferase ZDHHC18; ZDH18_HUMAN; Zdhhc18; Zinc finger DHHC domain-containing protein 18. |
| 纯化方法 | HPLC |
| 研究领域 | Signal Transduction > Metabolism > Lipid metabolism |
| 亚细胞定位 | Membrane; Multi-pass membrane protein |
| 相似性 | Belongs to the DHHC palmitoyltransferase family. ERF2/ZDHHC9 subfamily. Contains 1 DHHC-type zinc finger. |
| 功能 | Has palmitoyltransferase activity towards HRAS and LCK. |
| 保存条件 | Shipped at 4℃. Stored at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 背景资料 | Zinc-finger proteins contain DNA-binding domains and have a wide variety of functions, most of which encompass some form of transcriptional activation or repression. ZDHHC1 (zinc finger, DHHC-type containing 1), also known as ZNF377 (zinc finger protein 377) or C16orf1, is a 485 amino acid multi-pass membrane protein that contains one DHHC-type zinc finger. Expressed in fetal heart, lung and kidney and also present in adult lung and pancreas, ZDHHC1 functions as a palmitoyltransferase that catalyzes the conversion of palmitoyl-CoA and protein-cysteine to S-palmitoyl protein and CoA. Like ZDHHC1, ZDHHC5, ZDHHC6, ZDHHC7 and ZDHHC18 each contain one DHHC-type zinc finger through which they convey palmitoyltransferase activity against a broad range of substrates, including H-Ras, SNAP 25 and GABAA R proteins. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验or from the literature are missing. In this article, processing parameters for DNA, peptide, antibody, and carbohydrate microarrays are outlined. The applicability of the model experiments is demonstrated and described in detail on the example of short oligonucleotides.
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
. The use of graphitized carbon column instead of classical C18 reversed-phase material is shown to be well suited to detect low abundant glycoforms and to provide in one shot information regarding both the oligosaccharide structure and the amino acid
技术资料暂无技术资料 索取技术资料
